Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.BPH: Combination therapy
Evolving optimal treatment goals include relieving bothersome symptoms, alteration of disease progression and prevention of complications associated with LUTS/BPH. 1
Efficacy of combination therapy vs monotherapy
The efficacy of dutasteride plus tamsulosin has been investigated in the CombAT study. 2
Participants in the trial were men aged ≥50 years (n=4844) with a clinical diagnosis of BPH and an IPSS of ≥12, prostate volume 30 cm3 total serum PSA 1.5 ng/mL, and Qmax >5 mL/s and 15 mL/s with a minimum voided volume of 125 mL. 2
Efficacy in symptom relief
Dutasteride co-prescribed with tamsulosin offers rapid symptom improvement starting as early as tamsulosin monotherapy. 2
Dutasteride co-prescribed with tamsulosin offers significantly superior and sustained symptoms improvement vs tamsulosin monotherapy from months 9-48. 2
Alteration of disease progression and prevention of complications
Dutasteride co-prescribed with tamsulosin offers significant reduction in prostate volume vs tamsulosin monotherapy at Month 48. 2
Dutasteride co-prescribed with tamsulosin reduced the risk of disease progression and complications vs tamsulosin monotherapy at Month 48. 2
ARR, Absolute Risk Reduction; CI, confidence interval; RRR, Relative Risk Reduction.
References:
- McVary T, et al. AUA Guidelines on BPH 2010; reviewed and validity confirmed in 2014. Available at: http://www.auanet.org/documents/education/clinical-guidance/Benign-Prostatic_hyperplasia.pdf. Accessed March 2020.
- Roehrborn CG, et al. Eur Urol 2010;57:123–131.
Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.
